FDA lifts OncoMed partial hold

Share this article:

The FDA lifted its partial clinical hold on OncoMed's anti-Fzd7 vantictumab last week. The drug was being tested among non-small cell lung cancer chemotherapy patients, as well as patients with advanced HER2-negative breast cancer or advanced pancreatic cancer. The FDA froze the clinical trial in July over concern about “bone-related adverse events.”

Jefferies analyst Thomas Wei wrote in a Thursday research note that OncoMed expects to modify dosing regimens and enrollment criteria.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.